Smallpox Vaccine
Bavarian Nordic reports preliminary data from phase II study with Imvamune
Published in AIDS Weekly, January 22nd, 2007
The completed phase II study compared the safety and immunogenicity of Imvamune in 91 HIV infected subjects (CD4 > 350 cells/microl) to 60 healthy subjects. The study demonstrated that Imvamune is as equally well tolerated in HIV infected and healthy subjects.
Importantly, the immunogenicity data also revealed that 96% of HIV infected subjects previously not vaccinated against smallpox had a detectable antibody response 2 weeks after the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2007-01-22)
More Articles from AIDS Weekly
- HIV/AIDS Prevention
African approach to AIDS prevention works better than international medical technical approach - HIV/AIDS Therapy
Panacos files new drug application for second-generation HIV maturation inhibitor - HIV/AIDS
New HIV/AIDS study findings reported from University Federal do Rio of Janeiro - HIV/AIDS Cancer Epidemiology
Research from Erasme University, Department of Dermatology reveals new findings on HIV/AIDS cancer epidemiology - HIV/AIDS Cancer Genetics
Research from GeneticLab Co., Ltd. has provided new data on HIV/AIDS cancer genetics - HIV/AIDS Cancer Risk Factors
New HIV/AIDS cancer risk factors study findings have been published by scientists at Xinjiang Medical University - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
